Rapport Therapeutics, Inc. Common Stock (RAPP) - Net Assets
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has net assets worth $471.51 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($497.60 Million) and total liabilities ($26.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash efficiency ratio of Rapport Therapeutics, Inc. Common Stock to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $471.51 Million |
| % of Total Assets | 94.76% |
| Annual Growth Rate | 191.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 145.05 |
Rapport Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Rapport Therapeutics, Inc. Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025. For live valuation and market cap data, see RAPP company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $484.65 Million | +58.68% |
| 2024-12-31 | $305.43 Million | +1291.49% |
| 2023-12-31 | $-25.63 Million | -231.42% |
| 2022-12-31 | $19.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rapport Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22457600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.01% |
| Other Comprehensive Income | $546.00K | 0.11% |
| Other Components | $719.29 Million | 148.41% |
| Total Equity | $484.65 Million | 100.00% |
Rapport Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZAI LAB LTD0000006
F:1ZLB
|
$1.82 Billion |
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
$1.82 Billion |
|
AECC Aero Science and Technology Co Ltd
SHG:600391
|
$1.82 Billion |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
$1.82 Billion |
|
Beijing Qianjing Landscape Co
SHG:603778
|
$1.82 Billion |
|
North Chemical Industries Co Ltd
SHE:002246
|
$1.82 Billion |
|
Pharvaris BV
NASDAQ:PHVS
|
$1.82 Billion |
|
Siloam International Hospitals
JK:SILO
|
$1.82 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rapport Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 305,427,000 to 484,653,000, a change of 179,226,000 (58.7%).
- Net loss of 111,483,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- New share issuances of 269,439,000 increased equity.
- Other comprehensive income increased equity by 1,068,000.
- Other factors increased equity by 20,203,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-111.48 Million | -23.0% |
| Share Repurchases | $1.00K | -0.0% |
| Share Issuances | $269.44 Million | +55.59% |
| Other Comprehensive Income | $1.07 Million | +0.22% |
| Other Changes | $20.20 Million | +4.17% |
| Total Change | $- | 58.68% |
Book Value vs Market Value Analysis
This analysis compares Rapport Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 40.75x to 3.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.97 | $39.51 | x |
| 2023-12-31 | $-1.42 | $39.51 | x |
| 2024-12-31 | $14.73 | $39.51 | x |
| 2025-12-31 | $10.32 | $39.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rapport Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-23.00%) is above the historical average (-25.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -54.61% | 0.00% | 0.00x | 1.62x | $-12.60 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.22 Million |
| 2024 | -25.64% | 0.00% | 0.00x | 1.03x | $-108.85 Million |
| 2025 | -23.00% | 0.00% | 0.00x | 1.06x | $-159.95 Million |
Industry Comparison
This section compares Rapport Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $471.51 Million | -54.61% | 0.06x | $1.82 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more